HLB Pharmaceutical Co

HLB Pharmaceutical Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of HLB Pharmaceutical Co (047920.KQ) as of Oct 19, 2026 is -145.27 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 185.65 % — a change of -178.25% (lower).

FCF Conversion

-145.27 %

YoY

-178.25%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of HLB Pharmaceutical Co is 2025 -145.27 % . FCF Conversion Rate (FCF/EBITDA) of HLB Pharmaceutical Co was 2024 185.65 % . It decreases by -178.25% lower compared to the previous year.

The HLB Pharmaceutical Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
40.69 KRW
Jan 1, 2019
-9.27 KRW
Jan 1, 2020
4.52 KRW
Jan 1, 2021
384.35 KRW
Jan 1, 2022
48.09 KRW
Jan 1, 2023
116.19 KRW
Jan 1, 2024
185.65 KRW
Jan 1, 2025
-145.27 KRW
The HLB Pharmaceutical Co FCF Conversion history
YEARFCF ConversionYoY
-145.27 %-178.25%
185.65 %+59.78%
116.19 %+141.61%
48.09 %-87.49%
384.35 %+8,400.06%
4.52 %-148.80%
-9.27 %-122.77%
40.69 %-26.62%
55.45 %-106.43%
-862.23 %-757.90%
131.06 %-155.44%
-236.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HLB Pharmaceutical Co Stock analysis

What does HLB Pharmaceutical Co do? HLB Pharmaceutical Co Ltd, based in Namyangju, South Korea, operates in the Health Care sector, specializing in biotechnology-based pharmaceutical manufacturing. The company, listed on 21 December 2015, employs 230 people and produces a range of products including cimetidine, rabeprazole, and L-carnitine tablets, as well as OTC and ETC drugs like gynobetadine suppositories and commissioned medications. HLB Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB Pharmaceutical Co stock

FCF Conversion Rate (FCF/EBITDA) of HLB Pharmaceutical Co is -145.27 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of HLB Pharmaceutical Co changed from 185.65 % to -145.27 %, representing a -178.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) HLB Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s HLB Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — HLB Pharmaceutical Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — HLB Pharmaceutical Co